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Abstract
Background: The role of estrogen and estrogen receptors in oncogenesis has been investigated in various malignancies.
Recently our group identified estrogen receptor beta (ERb) expression as an independent prognostic factor in the
progression of human Malignant Pleural Mesothelioma (MMe), but the underlying mechanism by which ERb expression in
tumors determines clinical outcome remains largely unknown. This study is aimed at investigating the molecular
mechanisms of ERb action in MMe cells and disclosing the potential translational implications of these results.
Methods: We modulated ERb expression in REN and MSTO-211H MMe cell lines and evaluated cell proliferation and EGF
receptor (EGFR) activation.
Results: Our data indicate that ERb knockdown in ER positive cells confers a more invasive phenotype, increases anchorage
independent proliferation and elevates the constitutive activation of EGFR-coupled signal transduction pathways.
Conversely, re-expression of ERb in ER negative cells confers a more epithelioid phenotype, decreases their capacity for
anchorage independent growth and down-modulates proliferative signal transduction pathways. We identify a physical
interaction between ERb, EGFR and caveolin 1 that results in an altered internalization and in a selective reduced activation
of EGFR-coupled signaling, when ERb is over-expressed. We also demonstrate that differential expression of ERb influences
MMe tumor cell responsiveness to the therapeutic agent: Gefitinib.
Conclusions: This study describes a role for ERb in the modulation of cell proliferation and EGFR activation and provides a
rationale to facilitate the targeting of a subgroup of MMe patients who would benefit most from therapy with Gefitinib
alone or in combination with Akt inhibitors.
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Introduction
Malignant pleural mesothelioma (MMe) is a highly aggressive
tumor, most often associated with asbestos exposure, although a
role for SV40 and genetic susceptibility have also been proposed
[1]. The delayed clinical diagnosis of this tumor is due to the slow
progression of the malignancy [2]. The clinical prognosis is
generally poor, with a reported median survival from presentation
of 9–12 months. Several clinical prognostic factors have been
tentatively correlated to patient survival; these include histological
type (epithelioid, sarcomatoid or biphasic) and tumor grade [3,4].
We recently published data demonstrating that estrogen receptor
beta (ERb) is linked with better prognosis in MMe patients and is
likely to act as tumor repressor [5].
Estrogens exert their biological effects through two distinct
receptors: ERa and ERb. The ERs are transcribed from two
different genes and display specific tissue expression patterns as
well as distinct ligand specificities even though both bind the most
biologically active estrogen, 17b-estradiol [6]. This is confirmed by
the fact that mice lacking ERb (bER KO) display a very different
phenotype to those devoid of ERa (aERKO) [7–11]. In addition
to ligand binding ERb activity and sub-cellular distribution is also
regulated through its post-translational modification [12,13].
Evidences accumulated over the past decade describe a cross-talk
between ERs and EGFRs [14]. Work in this area has established a
requirement of ERs for some EGFR actions [15,16]. Recent
findings suggest the important role of EGFR (or similar receptors)
for estrogen signaling from the membrane in breast cancer. It has
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plasma membrane and utilizes the membrane EGFR to rapidly
signal through various kinase cascades that influence both
transcriptional and non-transcriptional actions of estrogen in
breast cancer cells [14,17]. Moreover, the activation of ERK1/2
through EGFRs and IGFR changes the phosphorylation state of
ERa to modulate receptor localization and transcriptional activity
[18,19]. More recently, it has become clear that ERb function can
also be modulated by phosphorylation in its N-terminal region, so
coupling ERb activity to growth factor signaling [20].
A large number of studies have focused on the expression of
growth factor receptors in MMe. EGFR is over-expressed in MMe
and this correlates significantly with increased tumor cell
proliferation and with the promotion of angiogenesis [21,22].
Despite these evidences two phase II studies with Erlotinib and
Gefitinib, two anti-phospho tyrosine kinase EGFR specific
molecules, did not show efficacy suggesting that further charac-
teristic apart from EGFR expression could be involved in
determining sensitivity to these agents [23,24].
The aim of this study is to achieve a better knowledge on the
molecular mechanism by which ERb exerts its tumor repressor
effects on MMe progression, in view of potential novel patient-
tailored therapies.
Results
ERb expression in ERs negative MMe cells reduces their
growth rate
To confirm the tumor repressor role of ERb in the modulation
of MMe cell growth, we expressed ERb in the constitutively ERs-
negative MSTO-211H MMe cell line, by using a pCXN2 based
plasmid expressing ERb.E R b expression conferred a more
epithelioid phenotype on the MSTO-211H cells compared to
mock transfected cells, characterized by a more cortical actin
distribution (Fig. 1B). 48 hours after transfection, total protein
extracts were prepared from mock- and ERb -transfected cells.
Equal amounts of protein from these cell extracts were Western
blotted and probed with ERb, phospho-EGFR, EGFR, phospho-
Akt, Akt, phospho-ERK1/2, ERK1/2 and cyclin D1-specific
antibodies; tubulin was added to confirm equal loading (Fig. 1A).
ERb protein expression was not detectable by immunoblot in
mock transfected cells, whereas it was in transfected cells. Western
blot analysis confirmed the efficacy of ERb expression to down
modulate EGFR, Akt and ERK1/2 phosphorylation without a
change in the total abundance of these proteins expression, while it
resulted in cyclin D1 protein reduction (Fig. 1A). Consistent with
our published data [5], ERb expression exerted at any considered
time a significant (p,0.05) suppressive effect on MSTO-211H cell
proliferation (Fig. 1C), without inducing apoptosis (data not
shown); we believe that in these cells PI3K/Akt could act in
concert with MAP kinase signaling to modulate cyclin D1
expression and cell cycle progression. Here we found that ERb
expression significantly reduced the number and the size of
colonies that MSTO-211H cells formed when cultured for 7 days
in soft agar. When colonies of more than 15 cells were considered
about 50% of reduction was seen in ERb expressing cells (Fig. 1D).
ERb silencing promotes MMe cell proliferation
We tested whether the suppression of ERb expression could
influence the rate of MMe cell proliferation. We previously
established that REN cells express moderate levels of ERb [5].
REN cells were transfected with an ERb-specific shRNA (shRNA-
ERb) to suppress expression of the receptor. 48 hours after
transfection, total protein extracts were prepared from mock- or
shRNA-ERb-transfected cells. Equal amounts of protein from
these cell extracts were Western blotted and probed with ERb,
phospho-EGFR, EGFR, phospho-Akt, Akt, phospho-ERK1/2,
ERK1/2 and cyclin D1-specific antibodies; tubulin was added to
confirm equal loading (Fig. 2A). Western blot analysis confirmed
the efficacy of the ERb-specific shRNA in suppressing expression
of the protein. Silencing of ERb expression in REN cells resulted
in increased EGFR, Akt and ERK1/2 phosphorylation without a
change in the total abundance of the proteins. However, the
abundance of cyclin D1 protein was elevated in cells suppressed in
ERb expression. Phase contrast microscopy imaging of cells grown
on a solid substrate (Fig. 2B) revealed that silencing of ERb
resulted in the loss of contact inhibition by the REN cells, which
allowed them to form dense foci rather than a confluent
monolayer. The cells were fixed and stained with phalloidin-
TRITC to discriminate changes in the actin cytoskeleton of the
REN cells. Suppression of ERb resulted in significant remodeling
of the actin structure within the REN cells, with a transition from a
largely cortical actin polymerization pattern to a highly defined
stress fibers organization. We next performed cell proliferation
experiments on cells grown on a solid surface and also tested the
effect of ERb suppression on the capacity of the REN cells for
anchorage-independent growth in semi-solid media. ERb sup-
pression significantly (p,0.05) increased the proliferation rate of
REN cells compared to wild-type controls at any considered time
(Fig. 2C). Moreover, ERb suppression resulted also in a 3 to 4-fold
increase in the number of colonies formed by the REN cells after 7
days of culture in soft agar (Fig. 2D).
ERb over-expression influences EGFR mediated signaling
and internalization
Therefore, we sought to investigate EGFR signaling in mock-
and ERb-transfected REN cells treated with EGF. Here we show
that the proliferation of REN cells is promoted by EGF treatment;
while transfection of REN cells with the ERb expression plasmid
significantly (p,0.05) inhibited the proliferation rate of these cells
both under basal conditions and following EGF exposure (Fig. 3A).
In response to EGF treatment of mock cells, EGFR became
phosphorylated and the ERK1/2 MAPK and Akt signaling
pathways were activated as demonstrated by the phosphorylation
state of these kinases (Fig. 3B). In ERb over-expressing cells there
was a reduced basal level of EGFR phosphorylation and a
diminished response to EGF treatment. This translated into a
reduced activation of signal transduction cascades with a slight
reduction in EGF induced ERK1/2 phosphorylation, but a
complete ablation of the EGF induced Akt phosphorylation
(Fig. 3B). To assess whether EGFR internalization was affected by
ERb over-expression, we evaluated the process of EGFR
internalization at 60 and 120 minutes of EGF treatment, in mock
and ERb over-expressing REN cells. As shown in Fig. 3C, EGFR
is almost completely internalized in mock-REN cells at both 60
and 120 minutes. In ERb-REN cells, EGFR is internalized at both
time points, although the process appears to be slower with respect
to mock cells, in particular at 60 minutes, suggesting a different
kinetic of internalization/recycling. These data were confirmed by
immunoblot analysis with anti-phospho tyrosine and anti-EGFR
antibodies of EGFR immunoprecipitated from plasma membrane
(Fig. 4D) of EGF treated mock and ERb over-expressing REN
cells.
ERb associates with EGFR and caveolin 1
Recently, it has been shown that EGFR may also follow the two
distinct endocytotic routes: one clathrin-dependent and one
clathrin-independent mediated by caveolin [25]. Published
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reduced activation of EGFR signaling [26]. The interaction
between androgen receptor and EGFR in the caveolae of prostate
cancer cells has been recently reported [27]. Consequently, we
investigated the physical interaction between ERb, EGFR and
caveolin-1 in REN cells. Firstly, membrane associated EGFR was
immunoprecipitated from lysates of REN cells treated 1 and 5
minutes with 5 ng/ml of human recombinant EGF. As shown in
Fig. 4A, Western blot analysis evidenced increased amounts of
ERb and caveolin 1 in EGFR immunoprecipitates upon EGF
stimuli. Membrane-associated EGFR was then immunoprecipi-
tated from mock- and ERb -transfected REN cells that were
treated for 5 minutes with EGF or left untreated, and then
analyzed by immunoblotting with EGFR, ERb and caveolin-1
Figure 1. ERb expression in ERs negative MMe cells reduces their growth rate. A) Western Blot analysis of cell extracts from mock- and ERb
expressing MSTO-211H cells. Representative of three separate experiments. B) Upper panels show phase contrast microphotographs (200X
magnification) of mock- or ERb-transfected MSTO-211H cells, visualizing the acquisition of a more epithelioid phenotype in transfected cells. Lower
panels show cells fixed in ethanol and stained for actin with phalloidin–TRITC as described. Note the actin rearrangement in ERb expressing cells
(400X magnification). C) Cell proliferation curves of mock- and ERb-transfected MSTO-211H cells cultured in complete medium for 24 and 48 hours.
Each value represents mean 6 SD (n=3). D) Total soft agar colony counts for mock- or ERb-transfected MSTO-211H cells were done by three
independent investigators microscopically visualizing individual colonies (clusters of 15 or more cells) in 10 random microscopic fields. Columns
represent the fold increase of the mean number of colonies in 10 fields; bars, SD; * p,0.05. Representative of three separate experiments.
doi:10.1371/journal.pone.0014110.g001
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EGFR to a minor extent in untreated cells however, EGF
treatment promoted the interaction and more ERb and caveolin-1
was immunoprecipitated with EGFR. Over-expression of ERb
resulted in an increased and EGF-independent association of these
proteins (Fig 4B). The ERb-EGFR-caveolin 1 interaction was
further investigated by confocal imaging in mock-transfected and
in ERb over-expressing REN cells (Fig. 4C). In mock-transfected
cells, there was little co-localization of ERb with either EGFR or
caveolin 1 within the cytoplasm or at the cell membrane; EGF
treatment resulted in a co-localization of ERb with EGFR and
caveolin 1 at discrete sites largely located within the cytoplasm of
treated cells. In ERb over-expressing REN cells ERb was
associated at high abundance with EGFR and caveolin 1 at
discrete sites within the cytoplasm, proximal to the cell membrane,
supporting co-immunoprecipitation data. The co-localization of
the proteins occurred independently of EGF treatment. The
redistribution of EGFR to discrete sites was specific to over-
expression of ERb and was not observed when ERa was over-
expressed in these cells (Fig. 4D).
ERb expression influences response of MMe cells to
Gefitinib
Gefitinib is an EGFR tyrosine kinase inhibitor that acts by
binding to the adenosine triphosphate (ATP)-binding site of the
enzyme, employed in the treatment of certain types of carcinomas.
However, lack of correlation between EGFR expression and
response to its tyrosine-kinase (TK) inhibitor Gefitinib has been
reported in different malignancies [28,29]. Mutations in EGFR-
TK domain have been associated with response in patients with
metastatic NSCLC [30]. The prevalence of such mutations in
mesothelioma is presently unknown but it seems that they are very
rare in mesothelioma [31]. Here we tested if ERb expression could
influence response to Gefitinib of MMe cells. The growth-
inhibitory effects of 5 mM Gefitinib were evaluated on mock,
ERb over-expressing or ERb silenced REN cells and in mock and
ERb expressing MSTO-211H cells (Fig. 5A). REN cells were
weakly sensitive to Gefitinib, and over-expression of ERb did not
significantly affect the sensitivity of these cells. The silencing of
ERb expression rendered the cells more sensitive to EGFR
antagonism, suggesting that the loss of ERb expression resulted in
Figure 2. ERb silencing promotes MMe cell proliferation. A) Western Blot analysis of cell extracts from mock- and ERb silenced REN cells.
Representative of three separate experiments. B) Upper panels show phase contrast microphotographs (200X magnification) of mock- or shERb-
transfected REN cells, visualizing the loss of contact inhibition and formation of foci in vitro. Lower panels show cells fixed in ethanol and stained with
phalloidin-TRITC to stain for actin as described. Note the actin rearrangement in ERb silenced cells (400X magnification). C) Cell proliferation curves of
mock- and shERb-transfected REN cells cultured in complete medium for 24 and 48 hours. Each value represents mean 6 SD (n=3). D) Total soft agar
colony counts for mock- or shERb-transfected REN cells were done by three independent investigators microscopically visualizing individual colonies
(clusters of 15 or more cells) in 10 random microscopic fields. Columns represent the fold increase of the mean number of colonies; bars, SD;
*p ,0.05. Representative of three separate experiments.
doi:10.1371/journal.pone.0014110.g002
ERb Function in Mesothelioma
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e14110ERb Function in Mesothelioma
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e14110a greater reliance of the cells upon EGFR-coupled signaling
pathways to support proliferation. These data were reinforced by
concordant data obtained with Gefitinib treatment of wild type
and ERb positive MSTO-211H cells (Fig. 5A).
Because EGFR signals through PI3-kinase/Akt and MAP/ERK
effectors pathways, phosphorylation of Akt and ERK 1/2 were
analyzed in ERb silenced REN and in MSTO-211H cells treated
with EGF in the absence or in the presence of Gefitinib. The basal
level of phosphorylated EGFR was increased in both cell types
upon EGF treatment and this resulted in increased Akt and
ERK1/2 phosphorylation. Gefitinib addition abrogated both basal
and EGF induced EGFR and ERK1/2 phosphorylation, but only
the EGF induced amount of phosphorylated Akt (Fig. 5B).
Discussion
ERa and ERb act as ligand-regulated transcription factors that
positively and negatively regulate gene expression, directly or
indirectly,throughthe activation ofproteinkinasesignaling.Models
of action have been described that involve synergism, as well as
competition between the two receptors, which is further refined by
other transcription factor interactions [32]. ERa and ERb display
differential expression profiles in estrogen-responsive tissues [33]
and shifts in their expression profile have also been identified in
malignant as compared to normal tissue and also through the stages
of cancer progression [34]. We have found that ERb is the
predominant isoform expressed in the pleural mesothelial cells and
patients with ERb over expressing tumors have a better survival [5].
Evidence points to ERb having a significant anti-neoplastic role in
MMe but the mechanisms underpinning this role remain to be
elucidated. In the present study we transfected the ERb-expressing
REN MMe cell line with ERb-specific shRNA to suppress
expression. This resulted in the promotion of anchorage-indepen-
dent cell growth and transition to a less epithelioid phenotype. The
mechanisms responsible for the increased cell growth and the
phenotypic shift that correlates with the loss of ERb expression are
important in understanding the role of ERb as a tumor suppressor.
Conversely, exogenous expression of ERb by the ERb-negative,
MSTO-211H MMe cell line resulted in suppression of anchorage-
independent cell growth and transition to a more epithelioid
phenotype. We previously demonstrated that in vitro ERb over-
expression caused a G2/M cell cycle phase arrest of MMe cells,
both ina ligand-dependent and -independent manner.The fact that
exogenous expression of ERb leads to inhibition of proliferation
correlates with in vivo data showing that ERb expression was lost in
the more aggressive sarcomatoid forms of the malignancy. In this
present study we found that MMe cells silenced or constitutively
devoid of ERb expression also display a more aggressive phenotype,
with the enhanced formation of foci when cultured in vitro and the
development of more abundant colonies when cultured in soft agar.
The modulation of cell cycle regulating proteins through ERb is
compatible with rapidly induced signaling and ablation of ERb
impacts upon the activation but not the expression of multiple
signaling intermediates in the MMe cells including Akt and Erk1/2.
Cross-talk between ERs and growth factor receptor-mediated
pathways at the plasma membrane has been described [35–37] and
functional interactions between ERband the epidermal growthfactor
receptor (EGFR) is documented [20]. Over expression of EGFR has
been detected in up to 68% of MMe tumors, however, the EGFR
expression level is itself not a good prognostic indicator. In the present
study we investigated the interaction between EGFR and ERb in
MMe cells. In cells which express high levels of ERs, ERb but not
ERa constitutively co-localizes with EGFR in caveolin 1 enriched
regions. This clustering interferes with EGFR phosphorylation in
response to its ligand, and alsoresults indelayed internalization of the
receptor and activation of coupled signaling cascades following
stimulation. As a consequence, ERb over-expressing cells are
insensitive to treatment with the EGFR inhibitor, Gefitinib, while
cells silenced in ERb expression display basal EGFR phosphorylation
and are more sensitive to Gefitinib. Our data give a possible
explanation for the inefficacy of EGFR inhibitors in phase II clinical
trials for ERb positive epithelioid MMe patients and opens the
possibility of a more successful employment of these drugs in more
aggressive, ERb negative, tumors either as a single agent or in
combination with Akt inhibitors.
Materials and Methods
Reagents and antibodies
The monoclonal antibody specific for a-tubulin and the polyclonal
antibodies for ERa,ERb,E G F R ,c a v e o l i n - 1 ,E R K 1 / 2M A Pk i n a s e
and cyclin D1 were from Santa Cruz Biotechnology (Santa Cruz,
CA). The monoclonal antibody specific for Akt and the phosphor-
ylation site-specific polyclonal antibodies for ERK1 (pThr202 and
pTyr204), ERK2 (pThr185 and pTyr187) MAP kinases, and Akt
(pSer473 and pThr308) were from Cell Signaling Technology
(Beverly, MA). The polyclonal antibodies for EGFR and ERb, used
in immunofluorescence analysis were obtained from Calbiochem
(Darmstadt, Germany) and Zymed-Invitrogen (Carlsbad, CA),
respectively. Protein A-Sepharose and ECL were from Amersham
Pharmacia Biotech (Uppsala, Sweden). Nitrocellulose membranes
and protein assay kits were from Bio-Rad (Hercules, CA). The
polyclonal phosphorylation site-specific antibody for EGFR
(pTyr1086), anti-mouse and anti-rabbit IgG horseradish peroxidase
conjugated antibodies, human recombinant EGF and all other
chemical reagents unless otherwise specified were from Sigma-
Aldrich (St Louis, MO). All reagents were of analytical grade. Culture
media, sera, antibiotics, and LipofectAMINE were from Invitrogen
(Carlsbad, CA). Gefitinib is an EGFR inhibitor also used clinically as
a chemotherapeutic agent and it is marketed by AstraZeneca.
Figure 3. ERb over-expression influences EGFR mediated signaling and internalization. A) The graph show the growth curves of mock-
and ERb-transfected REN cell treated for 24 and 48 hours with 5 ng/ml of EGF in 2% FBS culture medium. At each time point, the cells were assayed
for proliferation. Each value represents mean 6 SD (n=3). Adjacent to the graph is reported a representative Western blot analysis that documents
ERb expression. Tubulin staining indicates equal loading of the proteins. B) Mock- and ERb- transfected REN cells made quiescent for 2 hours were
treated with 5 ng/ml of EGF for 5 minutes and detergent extracted. Levels of phosphorylated EGFR, ERK 1/2 MAP kinases and Akt were analyzed by
immunoblotting. Membranes were also blotted with antibodies to EGFR, Erk1/2 and Akt to evaluate protein expression. Tubulin was blotted to show
equal amount of loading. Western blot analysis with anti ERb antibodies documents its expression in transfected cells. Representative of three
separate experiments. C) Evaluation of EGFR internalization was performed by Flow cytometry analysis on wild type and ERb expressing REN cells
treated 60 or 120 minutes with 10 ng/ml of human recombinant EGF. Histograms represent percentage of positive cells following incubation with
anti-EGFR antibody indicated for each condition 6 SD. Data are representative of three separate experiments. D)R e p r e s e n t a t i v e
immunoprecipitation experiment of membrane associated EGFR performed on mock and ERb over-expressing REN cells, treated 60 or 120 minutes
with 10 ng/ml of human recombinant EGF. Membrane was blotted with anti-pY and anti-EGFR antibodies.
doi:10.1371/journal.pone.0014110.g003
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The epithelioid MMe derived REN cell line that was used as the
principal experimental model in this investigation was isolated,
characterized [38] and kindly provided by Dr. S.M. Albelda
(University of Pennsylvania, Philadelphia, PA) and the MSTO-
211H cell line established from the pleural effusion of a patient
with biphasic mesothelioma of the lung [39] was obtained from the
Istituto Scientifico Tumori (IST)-Cell-bank, Genoa, Italy. Cells were
Figure 4. ERb associates with EGFR and caveolin 1. A) Co-immunoprecipitation experiments were performed on REN cells treated 1 and 5
minutes with 5 ng/ml of humanrecombinant EGF. ERb andcaveolin1 were detected by Western blot in immunoprecipitations of membraneassociated
EGFR. B) Co-immunoprecipitation experiments were performed on mock and ERb over-expressing REN cells treated 5 minutes with 5 ng/ml of human
recombinant EGF. ERb and caveolin 1 were detected by Western blot in immunoprecipitations of membrane associated EGFR. C) Confocal double
fluorescent microscopy analysis of red-labeled ERb with green-labeled EGFR or caveolin 1 in mock- (left panel) or ERb-transfected (right panel) REN cells
treated or not 5 minutes with 5 ng/ml of human recombinant EGF. D) Confocal fluorescent microscopy analysis showing the localization of green-
labeled EGFR and phalloidin-TRITC labeled actin filaments in mock and in ERb and ERa transfected REN cells. Nuclei were counterstained with DAPI.
doi:10.1371/journal.pone.0014110.g004
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14110Figure 5. ERb expression influences response of MMe cells to Gefitinib. A) Effects of Gefitinib on viable number were evaluated in mock-,
ERb- and shERb-transfected REN and in mock- and ERb- transfected MSTO-211H cell lines. Cells were incubated in serum-containing medium in the
presence of 5 mM Gefitinib for 24–48 hours. As control 0.1% DMSO vehicle alone was used. Results are expressed as number of viable cells relative to
control at 48 hours of treatment; bars, 6 SD; * p,0.05. Data are representative of three separate experiments. B) shERb-transfected REN and MSTO-
211H cells were treated with 5 ng/ml of EGF for 5 minutes in the absence or presence of 5 mM Gefitinib and detergent extracted. Levels of
phosphorylated EGFR, ERK 1/2 MAP kinases and Akt were analyzed by immunoblot. Membranes were also blotted with antibodies to EGFR, Erk1/2,
and Akt to evaluate protein expression. Tubulin was blotted to show equal amount of loading. Western blot analysis with anti ERb antibodies
documents expression in transfected cells. Representative of three separate experiments.
doi:10.1371/journal.pone.0014110.g005
ERb Function in Mesothelioma
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e14110cultured in RPMI medium supplemented with 10% foetal bovine
serum (FBS) at 37uC in a 5% CO2-humidified atmosphere. For
experimental purposes, the cells were maintained in the same
culture medium but lacking phenol red and containing charcoal-
stripped FBS. Mycoplasma infection was excluded by the use of
the Mycoplasma Plus
TM PCR Primer Set kit from Stratagene (La
Jolla, CA). Cells grown to 80% confluence in tissue culture dishes
were transiently transfected with the pCXN2 plasmid expressing
human wild type ERb (Addgene, Cambridge, MA) using
LipofectAMINE reagent as described by the manufacturer. Gene
silencing was achieved using an ERb-specific shRNA lentiviral
plasmid (pLKO.1-puro) by Sigma (St Louis, MO).
Cell lysis, immunoprecipitation and immunoblot
Cells wereextractedwith NP-40 lysis buffer (1% NP-40,150 mM
NaCl, 50 mM Tris-HCl pH 8, 5 mM EDTA, 10 mM NaF,
10 mM Na4P2O7, 0.4 mM Na3VO4,1 0mg/ml leupeptin, 4 mg/
ml pepstatin and 0.1 Unit/ml aprotinin). Cell lysates were
centrifuged at 13.000 x g for 10 minutes and the supernatants
were collected and assayed for protein concentration using the
Bradford protein assay reagent (Bio-Rad). Proteins were separated
by SDS-PAGE under reducing conditions. For co-immunoprecip-
itation experiments, cells were incubated with antibodies specific for
EGFR for 1 hour at 4uC, then lysed and a volume equivalent to
2 mg of extracted protein for each treatment was incubated in the
presence of 50 ml protein A-Sepharose beads. Following SDS-
PAGE, proteins were transferred to nitrocellulose, reacted with the
specific antibodies indicated and then detected with horseradish
peroxidase-conjugated secondary antibodies and the chemiolumi-
nescent ECL reagent. Densitometric analysis was performed using
the GS 250 Molecular Imager (Bio-Rad). For Cyclin D1 expression,
cells were extracted in RIPA Buffer (1% Triton X-100, 0.1% SDS,
1% Na-deoxycholate, 150 mM NaCl, 50 mM Tris-HCl pH 7,
0.4 mM Na3VO4,1 0 mg/ml leupeptin, 4 mg/ml pepstatin and
0.1 Unit/ml aprotinin) and analyzed as indicated above.
Cell proliferation as determined by direct counting
REN or MSTO-211H cells were seeded at a density of
1610
4 cells/well into six-well plates in growth medium supple-
mented with FBS and incubated overnight at 37uC in a humidified
environment containing 5% CO2 to allow the cells to become
adherent. Cells were alternatively transiently transfected with the
pCXN2 ERb plasmid or ERb shRNA, using the LipofectAMINE
reagent as described by the manufacturer. After 24 hours cells
were grown for a further 24–48 hours as indicated in complete
medium or treated with 5 ng/ml of human recombinant EGF in
2% charcoal-stripped FCS growth medium. Cells were then
trypsinized and stained with Trypan blue. The number of viable
cells was counted in a Burker chamber within 5 min of staining.
The same protocol was used to evaluate drugs sensitivity.
Assay for Anchorage-Independent Cell Growth
Anchorage-independent growth was determined using a modifica-
tion of previously described methods [40]. Briefly, a base layer of 0.6%
agar in complete medium was plated in six-well plates and allowed to
solidify (0.5 mg/ml Puromycin was added to wells containing shERb
transfected cells, while 250 mg/ml G418 was added to ERb
transfected cells). Next, wells were overlaid with 5610
3 cells per well
in a 0.3% agar. A growth control well was also included with 5610
3
cells in medium alone (no agar) for each cell line. The plates were
incubated at 37uC, 5% CO2 for 15 days and checked every 2 days for
colony formation. At day 7, individual colonies (defined as clusters of
15 or more cells) were counted in 10 random fields.
Confocal microscopy analysis
Immunofluorescence was performed using standard techniques.
Briefly, cells were plated (1610
5 cells) on glass cover slips and
allowed to adhere in a humidified atmosphere with 5% CO2 at
37uC. Wild type or transfected cells were then stimulated with
EGF (5 ng/ml for 5 minutes) and subsequently fixed with 4%
paraformaldehyde in PBS. Cells were permeabilized 5 minutes at
RT with 0.2% Triton-X in PBS. After fixation, the cells were
rinsed in PBS and incubated in a blocking solution containing 1%
Gelatin and 4% bovine serum albumin (BSA) in PBS for 1 hour.
Primary antibodies diluted in 2% BSA in PBS, were added in
combination to the fixed cells and incubated at room temperature
for 2 h. After washing in 2% BSA in PBS, the immunoreactivity
was revealed using Alexa Fluor 488 goat anti-mouse IgG or
tetramethylrhodamine isothiocynate (TRITC) goat anti-rabbit
secondary antibodies (Invitrogen, Paisely, UK) in 2% BSA in
PBS (1:200) used separately to stain the cells for 30 min at room
temperature. Negative controls were performed by substituting the
primary antibodies with the 2% BSA in PBS buffer. The immuno-
stained cells were rinsed with PBS and mounted in Vectashield
mountant (Vector Laboratories, Burlingame, CA) containing 49-6-
Diamidino-2-phenylindole (DAPI). Confocal imaging was per-
formed using a laser scanning LSM 510 confocal microscope (Carl
Zeiss, Welwyn Garden City, UK). Alexa Fluor 488, TRITC and
DAPI fluorophores were excited individually at 488 nm, 543 nm
and 364 nm respectively. Single focal plain scans of 0.8 mM depth
were performed at the mid diction of the cell monolayer using the
63x1.4 oil immersion objective.
Internalization assay by flow cytometry analysis
Cell surface EGFR expression was evaluated by flow cytometry
performed as described. Cells were grown in a Petri dish until
confluent, washed with PBS, detached using 0.1% trypsin–EDTA
and re-suspended in PBS with 1 mM CaCl2 and 1 mM MgCl2
supplemented with 4% FBS. After the indicated treatments, cells
were incubated for 30 minutes at 4uC with the monoclonal anti-
EGFR antibody or non-specific IgG as control, washed twice with
PBS and further incubated with fluorescein isothiocynate (FITC)-
conjugated goat anti-mouse secondary antibody (1:200) for 30
minutes. After washing twice, cells were fixed with 3%
paraformaldehyde in PBS at room temperature for 15 minutes
and washed twice in PBS. FITC fluorescent emission was detected
over the range 515–555 nm using the FL-1 detector of a FACScan
flow cytometer (Becton Dickinson, Franklin Lakes, NJ) equipped
with 15 mW argon–ion laser for excitation. Debris was gated out
by establishing a region around the population of interest on the
Forward Scatter versus Side Scatter dot plot. For each sample,
10.000 events in the region of interest were recorded at a flow rate
of 200–300 cells/s. Data were processed with analysis software
LYSYS II (Becton Dickinson) and are expressed as median value
of EGFR expressing cells of the fluorescence histograms
normalized to the corresponding negative control obtained by
omitting the primary antibody.
Statistical analysis
Statistical differences between treatment groups were measured
using the one-tailed Student’s test.
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